Review



ps6 af488  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc ps6 af488
    Ps6 Af488, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 3711 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ps6-af488+antibody/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Antibody/pmc06684453-51-31-34
    Average 96 stars, based on 3711 article reviews
    ps6 af488 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Ex Vivo:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Expressing:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Flow Cytometry:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Inhibition:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Infection:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Activity Assay:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Cell Culture:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Recombinant:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    ATP Assay:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Plasmid Preparation:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Software:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Sample Prep:

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport
    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).



    Similar Products

    90
    Becton Dickinson anti-ps6-af488 p235/p236 antibody
    Anti Ps6 Af488 P235/P236 Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ps6-af488+antibody/p62+antibody/pm34922003-54-40-44
    Average 90 stars, based on 1 article reviews
    anti-ps6-af488 p235/p236 antibody - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc ps6 af488
    Ps6 Af488, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ps6-af488+antibody/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Antibody/pmc06684453-51-31-34
    Average 96 stars, based on 1 article reviews
    ps6 af488 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc ps6 af488; 2f9 antibody
    Ps6 Af488; 2f9 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ps6-af488+antibody/anti+pakt+s505/pmc06684453-51-33-34
    Average 90 stars, based on 1 article reviews
    ps6 af488; 2f9 antibody - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc ps6-af488 antibody
    (A) Cells from HIV-1+ participants have increased mTOR signaling, compared to cells from healthy controls. PBMCs from viremic HIV-1+ research participants and healthy controls (HC) were surface phenotyped to identify CD4 T cells and analyzed without any ex vivo stimulation for the expression of the canonical phosphorylated target downstream of mTOR, phosphorylated ribosomal <t>protein</t> <t>S6</t> (p-S6), by multiparameter flow cytometry. Each group had cells from 4 independent donors. Means and SDs of data are shown. (B) mTOR inhibition decreased p-S6 in cells from HIV-1+ participants. (C) mTOR inhibition decreased p-S6 in cells from both viremic and ART-treated HIV-1+ participants. (B and C) PBMCs from viremic HIV-infected (n = 13) (B) and ART-suppressed HIV-infected (n = 14) (C) study participants were treated with either mTORi or DMSO vehicle for 8 h ex vivo and analyzed for mTOR activity (p-S6) by flow cytometry. A representative histogram is presented for PBMCs obtained from a HIV-infected donor cultured in the absence and presence of mTORi. Data from PBMCs for all of the participants are plotted in (C). The means and SDs of data are shown. Significant differences were determined by 2-tailed Student’s t tests: *p < 0.05, **p < 0.01, and ***p < 0.005.
    Ps6 Af488 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ps6-af488+antibody/anti+pakt+s505/pmc07389891-692-27-28
    Average 90 stars, based on 1 article reviews
    ps6-af488 antibody - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Cells from HIV-1+ participants have increased mTOR signaling, compared to cells from healthy controls. PBMCs from viremic HIV-1+ research participants and healthy controls (HC) were surface phenotyped to identify CD4 T cells and analyzed without any ex vivo stimulation for the expression of the canonical phosphorylated target downstream of mTOR, phosphorylated ribosomal protein S6 (p-S6), by multiparameter flow cytometry. Each group had cells from 4 independent donors. Means and SDs of data are shown. (B) mTOR inhibition decreased p-S6 in cells from HIV-1+ participants. (C) mTOR inhibition decreased p-S6 in cells from both viremic and ART-treated HIV-1+ participants. (B and C) PBMCs from viremic HIV-infected (n = 13) (B) and ART-suppressed HIV-infected (n = 14) (C) study participants were treated with either mTORi or DMSO vehicle for 8 h ex vivo and analyzed for mTOR activity (p-S6) by flow cytometry. A representative histogram is presented for PBMCs obtained from a HIV-infected donor cultured in the absence and presence of mTORi. Data from PBMCs for all of the participants are plotted in (C). The means and SDs of data are shown. Significant differences were determined by 2-tailed Student’s t tests: *p < 0.05, **p < 0.01, and ***p < 0.005.

    Journal: Cell reports

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport

    doi: 10.1016/j.celrep.2020.107810

    Figure Lengend Snippet: (A) Cells from HIV-1+ participants have increased mTOR signaling, compared to cells from healthy controls. PBMCs from viremic HIV-1+ research participants and healthy controls (HC) were surface phenotyped to identify CD4 T cells and analyzed without any ex vivo stimulation for the expression of the canonical phosphorylated target downstream of mTOR, phosphorylated ribosomal protein S6 (p-S6), by multiparameter flow cytometry. Each group had cells from 4 independent donors. Means and SDs of data are shown. (B) mTOR inhibition decreased p-S6 in cells from HIV-1+ participants. (C) mTOR inhibition decreased p-S6 in cells from both viremic and ART-treated HIV-1+ participants. (B and C) PBMCs from viremic HIV-infected (n = 13) (B) and ART-suppressed HIV-infected (n = 14) (C) study participants were treated with either mTORi or DMSO vehicle for 8 h ex vivo and analyzed for mTOR activity (p-S6) by flow cytometry. A representative histogram is presented for PBMCs obtained from a HIV-infected donor cultured in the absence and presence of mTORi. Data from PBMCs for all of the participants are plotted in (C). The means and SDs of data are shown. Significant differences were determined by 2-tailed Student’s t tests: *p < 0.05, **p < 0.01, and ***p < 0.005.

    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Techniques: Ex Vivo, Expressing, Flow Cytometry, Inhibition, Infection, Activity Assay, Cell Culture

    KEY RESOURCES TABLE

    Journal: Cell reports

    Article Title: mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport

    doi: 10.1016/j.celrep.2020.107810

    Figure Lengend Snippet: KEY RESOURCES TABLE

    Article Snippet: The following antibodies were used: CD3-BV510 (BD Biosciences, #563109), CD4-PE-Cy7 (Biolegend, #344612), CD71-AF700 (BD Biosciences, #563769), Bcl-2-PE (BD Biosciences, # 340651), pStat5-PE-CF594 (pY694) (BD Biosciences, #562501), and pS6-AF488 (Cell Signaling Technology, #5018).

    Techniques: Recombinant, ATP Assay, Plasmid Preparation, Expressing, Software